Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Publication
, Journal Article
Li, J; Armstrong, AJ
Published in: Clin Adv Hematol Oncol
May 2015
Duke Scholars
Published In
Clin Adv Hematol Oncol
ISSN
1543-0790
Publication Date
May 2015
Volume
13
Issue
5
Start / End Page
293 / 298
Location
United States
Related Subject Headings
- Treatment Outcome
- Taxoids
- Radium
- Prostatic Neoplasms, Castration-Resistant
- Oncology & Carcinogenesis
- Neoplasm Metastasis
- Male
- Humans
- Docetaxel
- Clinical Decision-Making
Citation
APA
Chicago
ICMJE
MLA
NLM
Li, J., & Armstrong, A. J. (2015). Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol, 13(5), 293–298.
Li, Jing, and Andrew J. Armstrong. “Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.” Clin Adv Hematol Oncol 13, no. 5 (May 2015): 293–98.
Li J, Armstrong AJ. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2015 May;13(5):293–8.
Li, Jing, and Andrew J. Armstrong. “Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.” Clin Adv Hematol Oncol, vol. 13, no. 5, May 2015, pp. 293–98.
Li J, Armstrong AJ. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2015 May;13(5):293–298.
Published In
Clin Adv Hematol Oncol
ISSN
1543-0790
Publication Date
May 2015
Volume
13
Issue
5
Start / End Page
293 / 298
Location
United States
Related Subject Headings
- Treatment Outcome
- Taxoids
- Radium
- Prostatic Neoplasms, Castration-Resistant
- Oncology & Carcinogenesis
- Neoplasm Metastasis
- Male
- Humans
- Docetaxel
- Clinical Decision-Making